Login

Bobcat339 (hydrochloride)

CAT:
804-HY-111558A-01
Size:
5 mg
Price:
Ask
For price, please contact [email protected]
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Bobcat339 (hydrochloride) - image 1

Bobcat339 (hydrochloride)

  • CAS Number: 2436747-44-1
  • UNSPSC Description: Bobcat339 hydrochloride is a potent and selective cytosine-based inhibitor of TET enzyme, with the IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 hydrochloride is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription[1].
  • Target Antigen: DNA Methyltransferase; TET Protein
  • Type: Reference compound
  • Related Pathways: Epigenetics
  • Applications: Cancer-programmed cell death
  • Field of Research: Cancer
  • Assay Protocol: https://www.medchemexpress.com/Bobcat339_hydrochloride.html
  • Purity: 99.59
  • Solubility: DMSO : 125 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL
  • Smiles: NC1=NC(N(C2=CC=CC(C3=CC=CC=C3)=C2)C=C1Cl)=O.Cl
  • Molecular Weight: 334.20
  • References & Citations: [1]Chua GNL, et al. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019 Jan 31;10(2):180-185.Bioelectrochemistry. 2023 Apr 4;152:108433.|Cancers (Basel). 2022 Jun 16;14(12):2983.|Cell Death Dis. 2024 Jun 1;15(6):387.|Clin Epigenetics. 2024 Oct 2;16(1):136.|Clin Sci. 2023 Aug 31;137(16):1265-1283.|Environ Sci Technol. 2021 Feb 11.|J Clin Invest. 2023 Aug 29;e170173.|J Pharm Biomed Anal. 2021 Jun 24;203:114228.|Mol Pain. 2022 Apr;18:17448069221143671.|Neuropharmacology. 2023 Nov 24:109799.|Sci Total Environ. 2024 Apr 1:919:170905.|Theranostics. 2021 Jun 11;11(16):7640-7657.|Aquaculture. 2023: 739234.|Br J Pharmacol. 2024 Jun 16.|Brain Sci. 2023 Apr 10, 13(4), 644.|Eur J Pharmacol. 2024 Aug 23:176931.|Research Square Print. 2023 Mar 14.|Research Square Print. November 29th, 2022.
  • Shipping Conditions: Room Temperature
  • Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
  • Clinical Information: No Development Reported